IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. - Martin-Broto J; Strauss SJ; Palmerini E; Valverde C; Sebio A; Redondo A; Stacchiotti S; Grignani G; Aliberti S; Diaz-Beveridge R; Billalabeitia EG; Cruz J; et al. (Cancer communications (London, England), 2026)